ES2099245T3 - Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth). - Google Patents
Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth).Info
- Publication number
- ES2099245T3 ES2099245T3 ES92900612T ES92900612T ES2099245T3 ES 2099245 T3 ES2099245 T3 ES 2099245T3 ES 92900612 T ES92900612 T ES 92900612T ES 92900612 T ES92900612 T ES 92900612T ES 2099245 T3 ES2099245 T3 ES 2099245T3
- Authority
- ES
- Spain
- Prior art keywords
- osteoporosis
- grf
- pth
- treatment
- release factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 4
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 4
- 239000000199 parathyroid hormone Substances 0.000 title abstract 4
- 208000001132 Osteoporosis Diseases 0.000 title abstract 3
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910052738 indium Inorganic materials 0.000 abstract 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UN METODO PARA EL TRATAMIENTO DE LA OSTEOPOROSIS, ESPECIALMENTE DE LA OSTEOPOROSIS POST-MENOPAUSICA, QUE CONSISTE EN ADMINISTRAR A UN PACIENTE, DE FORMA PERIODICA PERO CONTINUA, EL FACTOR DE LIBERACION DE LA HORMONA DE CRECIMIENTO, GRF(1-44)-NH2, O UN ANALOGO BIOLOGICAMENTE ACTIVO DEL MISMO Y ADMINISTRAR AL MISMO TIEMPO UNA HORMONA PARATIROIDEA, PTH(1-34)-NH2 Y SEGUIR CON LA ADMINISTRACION HASTA QUE AUMENTE LA MASA OSEA Y EL EQUILIBRIO DE CALCIO DEL PACIENTE SE VUELVA POSITIVO E INDIQUE UNA ACUMULACION DE MINERAL EN EL ESQUELETO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61754390A | 1990-11-26 | 1990-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2099245T3 true ES2099245T3 (es) | 1997-05-16 |
Family
ID=24474060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92900612T Expired - Lifetime ES2099245T3 (es) | 1990-11-26 | 1991-11-01 | Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5164368A (es) |
| EP (1) | EP0559751B1 (es) |
| JP (1) | JP2557779B2 (es) |
| AT (1) | ATE150648T1 (es) |
| AU (1) | AU645874B2 (es) |
| CA (1) | CA2096350C (es) |
| DE (1) | DE69125394T2 (es) |
| DK (1) | DK0559751T3 (es) |
| ES (1) | ES2099245T3 (es) |
| FI (1) | FI106776B (es) |
| IE (1) | IE913858A1 (es) |
| NZ (1) | NZ240482A (es) |
| WO (1) | WO1992009304A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9408019A (pt) * | 1993-11-09 | 1997-08-26 | Merck & Co Inc | Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto |
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5492920A (en) * | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US6074840A (en) | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
| US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| US5731317A (en) * | 1995-03-10 | 1998-03-24 | Merck & Co., Inc. | Bridged piperidines promote release of growth hormone |
| US5700775A (en) * | 1995-03-24 | 1997-12-23 | Gutniak; Mark K. | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury |
| US5559128A (en) * | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
| US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| JP2000512274A (ja) * | 1996-05-31 | 2000-09-19 | ノボ ノルディスク アクティ―ゼルスカブ | 骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤 |
| AU2002300896B2 (en) * | 1997-06-19 | 2006-03-30 | Nps Pharmaceuticals, Inc. | Method of enhancing bone mineral density |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
| WO1999006563A1 (en) | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| AU6510999A (en) * | 1998-10-07 | 2000-04-26 | Board Of Trustees Of The University Of Arkansas, The | Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| AU1525700A (en) | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| RU2006143544A (ru) * | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| CN109053742B (zh) | 2009-12-01 | 2021-06-15 | Abbvie 公司 | 新的三环化合物 |
| AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870094A (en) * | 1984-05-02 | 1989-09-26 | Uniroyal Chemical Company, Inc. | Substituted imidazoles and triazoles |
| US4710382A (en) | 1985-09-27 | 1987-12-01 | Recker Robert R | Treatment for osteoporosis using hGRF(1-40)NH2 |
| US4870054A (en) | 1985-09-27 | 1989-09-26 | Recker Robert R | Treatment for osteoporosis using GRF or a biologically active analog thereof |
| US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| US4833123A (en) * | 1987-10-08 | 1989-05-23 | Sumitomo Chemical Company Limited | Yellow dye-donor element used in thermal transfer and thermal transfer and thermal transfer sheet using it |
| AU617426B2 (en) * | 1988-01-29 | 1991-11-28 | Upjohn Company, The | Growth hormone releasing factor analogs |
-
1991
- 1991-11-01 AU AU90735/91A patent/AU645874B2/en not_active Ceased
- 1991-11-01 AT AT92900612T patent/ATE150648T1/de not_active IP Right Cessation
- 1991-11-01 WO PCT/US1991/008106 patent/WO1992009304A1/en active IP Right Grant
- 1991-11-01 CA CA002096350A patent/CA2096350C/en not_active Expired - Fee Related
- 1991-11-01 EP EP92900612A patent/EP0559751B1/en not_active Expired - Lifetime
- 1991-11-01 DE DE69125394T patent/DE69125394T2/de not_active Expired - Fee Related
- 1991-11-01 JP JP4501851A patent/JP2557779B2/ja not_active Expired - Fee Related
- 1991-11-01 DK DK92900612.0T patent/DK0559751T3/da active
- 1991-11-01 ES ES92900612T patent/ES2099245T3/es not_active Expired - Lifetime
- 1991-11-04 US US07/787,051 patent/US5164368A/en not_active Expired - Lifetime
- 1991-11-05 IE IE385891A patent/IE913858A1/en not_active IP Right Cessation
- 1991-11-05 NZ NZ240482A patent/NZ240482A/en unknown
-
1993
- 1993-05-26 FI FI932385A patent/FI106776B/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| DK0559751T3 (da) | 1997-10-06 |
| DE69125394D1 (de) | 1997-04-30 |
| FI106776B (fi) | 2001-04-12 |
| AU645874B2 (en) | 1994-01-27 |
| FI932385A0 (fi) | 1993-05-26 |
| EP0559751B1 (en) | 1997-03-26 |
| EP0559751A1 (en) | 1993-09-15 |
| DE69125394T2 (de) | 1997-08-21 |
| EP0559751A4 (en) | 1994-07-13 |
| NZ240482A (en) | 1997-06-24 |
| JP2557779B2 (ja) | 1996-11-27 |
| WO1992009304A1 (en) | 1992-06-11 |
| AU9073591A (en) | 1992-06-25 |
| CA2096350A1 (en) | 1992-05-27 |
| JPH06502863A (ja) | 1994-03-31 |
| CA2096350C (en) | 2001-10-16 |
| FI932385L (fi) | 1993-05-26 |
| US5164368A (en) | 1992-11-17 |
| ATE150648T1 (de) | 1997-04-15 |
| IE913858A1 (en) | 1992-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2099245T3 (es) | Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth). | |
| ES2190244T3 (es) | Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. | |
| CA2124792A1 (en) | Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone | |
| ES2055845T3 (es) | Composicion farmaceutica para el tratamiento de la osteoporosis. | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| IL78342A (en) | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof | |
| ZA923980B (en) | Hepatocyte Growth stimulation | |
| ATE208612T1 (de) | Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen | |
| ES2132066T3 (es) | Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg). | |
| ES2104697T3 (es) | Formulados farmaceuticos. | |
| PT693924E (pt) | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos | |
| DK0670729T3 (da) | Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme | |
| CY1110287T1 (el) | Χρηση της ανθρωπινης παραθυρεοειδους ορμονης | |
| NO305581B1 (no) | Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose | |
| ES2111163T3 (es) | Uso de fosfonatos para el tratamiento de la osteoporosis. | |
| GEP20033095B (en) | Parathyroid Hormone Analogues for the Treatment of Osteoporosis | |
| AR025719A1 (es) | Metodo para tratamiento por monitoreo con una hormona paratiroidea | |
| EP0904094A4 (en) | TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN | |
| ATE329613T1 (de) | Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas | |
| ECSP982660A (es) | USO DE ANALOGOS DEL PTHrP EN LA CICATRIZACION DE FRACTURAS | |
| ECSP993107A (es) | Metodo para incrementar la resistencia y dureza del hueso | |
| AR001226A1 (es) | Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea | |
| PE20030552A1 (es) | APLICACION TERAPEUTICA DE AGONISTAS SELECTIVOS DEL ESTROGENORECEPTOR BETA (ERß) PARA PROVOCAR EFECTOS SOMATOTROPOS, ORGANOTROPOS Y ANTICATABOLICOS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 559751 Country of ref document: ES |